Immune Response to Hepatitis C Virus
NCT00006301 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89
Last updated 2019-12-03
Summary
This study will identify and characterize immune factors involved in hepatitis C infection and elimination of the virus. Individual responses to hepatitis C infection vary; some people are able to eliminate the virus, whereas others remain chronically infected. This study may identify factors important in preventing infection that may be of help in developing a vaccine or more effective treatments.
People over 18 years old who have been exposed to hepatitis C virus may participate in this study. Subjects will be recruited from the National Institutes of Health, Inova Fairfax Hospital, Occupational Medical Services-IDP P.C., Washington Hospital Center and Holy Cross Hospital, all in the Washington, D.C. metropolitan area. Individual patients from other centers will also be recruited on a case by case basis.
Participants will have 40 to 60 cc (1 to 2 ounces) of blood drawn at seven intervals. The first collection will be as soon as possible after exposure to hepatitis C virus and then again at 2, 4, 6, 12, 24, and 48 weeks after exposure. The white blood cells will be studied for their response to the virus, and markers for infection will be followed. If infection develops, additional samples of blood may be requested, and patients will be offered evaluation for treatment. Test results will be kept confidential and will not be entered into any medical records.
Conditions
- Hepatitis C
Sponsors & Collaborators
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
lead NIH
Principal Investigators
-
Theo Heller, M.D. · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-09-24
- Completion
- 2015-03-24
Countries
- United States
Study Locations
More Related Trials
-
Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects
NCT01459419 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
NCT02532907 ·Status: COMPLETED
-
Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients
NCT00703560 ·Status: COMPLETED
-
Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.
NCT00422838 ·Status: COMPLETED
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
NCT03520660 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Therapeutic Hepatitis C Virus Vaccine
NCT04318379 ·Status: UNKNOWN ·Phase: PHASE1
-
Immune Monitoring of Hepatitis C Under DAA Therapy
NCT02904603 ·Status: UNKNOWN
-
Identification of Hepatitis C Virus (HCV) Specific T Cells
NCT01534728 ·Status: COMPLETED
-
The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients
NCT01335230 ·Status: COMPLETED
-
Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)
NCT01329913 ·Status: COMPLETED ·Phase: PHASE1
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
NCT01888900 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
NCT02118012 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients
NCT01062659 ·Status: WITHDRAWN
-
Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)
NCT01930058 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
NCT01740791 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
NCT01206933 ·Status: COMPLETED
-
Hepatitis C Lab Testing Comparison Study
NCT06380166 ·Status: TERMINATED
-
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
NCT00735969 ·Status: COMPLETED ·Phase: PHASE2
-
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
NCT01667081 ·Status: COMPLETED
-
An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C
NCT04301882 ·Status: UNKNOWN
-
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
NCT01165359 ·Status: COMPLETED ·Phase: PHASE1
-
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
NCT00056862 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
NCT01508156 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
IdB 1016 Treatment for Hepatitis C Disease
NCT00055445 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
NCT00565539 ·Status: COMPLETED ·Phase: PHASE1